Ian Forrest
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ian Forrest has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- A. John Simpson
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
2 shared publications Amaran Krishnan
Northern Oesophago-Gastric Unit, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK
1 shared publicationAnne-Marie Bourke
Newcastle Upon Tyne Hospitals NHS Foundation Trust and Marie Curie Hospice
1 shared publication- C. Donaldson
Newcastle Upon Tyne Hospitals NHS Trust, Queen Victoria Rd, Newcastle upon Tyne, NE1 4LP, UK
1 shared publication - Christopher Ward
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
1 shared publication - Colm Leonard
North West Lung Centre, Wythenshawe Hospital, Manchester M23 9LT, UK
1 shared publication
Latest Publications
- 23 July 2019
- Published by Springer Nature
- p. 139-158
Interstitial Lung Disease
- Open Access
- 1 October 2018
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 4 (4) , 00051-2018
Reflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach
After MDT work-up and review, gastro-oesophageal reflux and pulmonary aspiration were found to be common in IPF patients; surgery was recommended in only 10%http://ow.ly/rO3T30lU17o
- 1 October 2018
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 4 (4) , 00051-2018
Open AccessReflux in idiopathic pulmonary fibrosis: treatment informed by an integrated approach
After MDT work-up and review, gastro-oesophageal reflux and pulmonary aspiration were found to be common in IPF patients; surgery was recommended in only 10%http://ow.ly/rO3T30lU17o
- Open Access
- 3 November 2017
- Published by Wiley in Clinical and Translational Medicine
- Vol. 6 (1) , 41
Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Background: Nintedanib has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). It was approved by the National Institute for Health and Care Excellence (NICE) in January 2016 for IPF patients with a forced vital capacity (FVC) of 50–80% in the United Kingdom (UK).Aim: To report real world data about our early clinical experience using nintedanib in 187 patients with a multi‐disciplinary (MDT) diagnosis of IPF in a manufacturer funded patient in need scheme (three UK centres) prior to NICE approval.Methods: All patients with a MDT diagnosis of IPF from December 2014 to January 2016 commenced on nintedanib were included. Demographic details, adverse events (AEs) and where available lung function results were retrospectively collected from clinical letters.Results: 187 patients (76% males) with a median age of 72 years (49–89) were treated with nintedanib. The average pre‐treatment FVC was 81.1 ± 19.8% and diffusion capacity of the lungs for carbon monoxide was 43.9 ± 15% (n = 82). Fifty percent of patients started nintedanib because they were ineligible for pirfenidone due to an FVC > 80%. The median treatment course was 8 ± 4 months. The majority of patients experienced 1–3 AEs with nintedanib (52%, n = 97). The most frequent AEs were diarrhoea (50%), nausea (36%), reduced appetite (24%), tiredness (20%) and gastro‐oesophageal reflux (18%). The majority of AEs resulted in no change in treatment (64%, n = 461). 21% (n = 150) of AEs resulted in a dose reduction and 13% (n = 94) necessitated discontinuation of treatment. 1 in 5 patients discontinued treatment either temporarily or on a permanent basis during the monitoring period. In a select cohort of patients, a statistically significant greater proportion of patients remained stable or improved and a lower proportion declined, as depicted by FVC changes of > 5% after nintedanib commencement (P < 0.05 using Chi squared test).Conclusions: Nintedanib is well tolerated and has an acceptable safety profile. Only 8% of those reporting diarrhoea discontinued treatment either on a temporary or permanent basis. There were no signals with respect to increased cardiovascular morbidity or major bleeding risk. This is in keeping with the INPULSIS clinical trial findings but in a real world cohort.
- 3 November 2017
- Published by Wiley in Clinical and Translational Medicine
- Vol. 6 (1) , 41
Open AccessEarly clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres
Background: Nintedanib has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). It was approved by the National Institute for Health and Care Excellence (NICE) in January 2016 for IPF patients with a forced vital capacity (FVC) of 50–80% in the United Kingdom (UK).Aim: To report real world data about our early clinical experience using nintedanib in 187 patients with a multi‐disciplinary (MDT) diagnosis of IPF in a manufacturer funded patient in need scheme (three UK centres) prior to NICE approval.Methods: All patients with a MDT diagnosis of IPF from December 2014 to January 2016 commenced on nintedanib were included. Demographic details, adverse events (AEs) and where available lung function results were retrospectively collected from clinical letters.Results: 187 patients (76% males) with a median age of 72 years (49–89) were treated with nintedanib. The average pre‐treatment FVC was 81.1 ± 19.8% and diffusion capacity of the lungs for carbon monoxide was 43.9 ± 15% (n = 82). Fifty percent of patients started nintedanib because they were ineligible for pirfenidone due to an FVC > 80%. The median treatment course was 8 ± 4 months. The majority of patients experienced 1–3 AEs with nintedanib (52%, n = 97). The most frequent AEs were diarrhoea (50%), nausea (36%), reduced appetite (24%), tiredness (20%) and gastro‐oesophageal reflux (18%). The majority of AEs resulted in no change in treatment (64%, n = 461). 21% (n = 150) of AEs resulted in a dose reduction and 13% (n = 94) necessitated discontinuation of treatment. 1 in 5 patients discontinued treatment either temporarily or on a permanent basis during the monitoring period. In a select cohort of patients, a statistically significant greater proportion of patients remained stable or improved and a lower proportion declined, as depicted by FVC changes of > 5% after nintedanib commencement (P < 0.05 using Chi squared test).Conclusions: Nintedanib is well tolerated and has an acceptable safety profile. Only 8% of those reporting diarrhoea discontinued treatment either on a temporary or permanent basis. There were no signals with respect to increased cardiovascular morbidity or major bleeding risk. This is in keeping with the INPULSIS clinical trial findings but in a real world cohort.